Incyte Stock Forecast, Price & News

Incyte's stock was trading at $71.90 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, INCY stock has increased by 20.8% and is now trading at $86.88.
View which stocks have been most impacted by COVID-19.

23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last year. There are currently 10 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Incyte.

Incyte is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Incyte.

Incyte Co. (NASDAQ:INCY) released its quarterly earnings results on Tuesday, August, 4th. The biopharmaceutical company reported $1.04 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.68 by $0.36. The biopharmaceutical company had revenue of $688 million for the quarter, compared to analyst estimates of $617.55 million. Incyte had a negative net margin of 8.00% and a negative return on equity of 8.06%. The firm's quarterly revenue was up 29.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.75 EPS.
View Incyte's earnings history.

23 analysts have issued twelve-month price targets for Incyte's shares. Their forecasts range from $83.00 to $124.00. On average, they expect Incyte's share price to reach $102.30 in the next year. This suggests a possible upside of 17.7% from the stock's current price.
View analysts' price targets for Incyte.

Incyte saw a increase in short interest during the month of August. As of August 14th, there was short interest totaling 5,440,000 shares, an increase of 11.9% from the July 30th total of 4,860,000 shares. Based on an average daily trading volume, of 1,420,000 shares, the days-to-cover ratio is presently 3.8 days.
View Incyte's Short Interest.

Some companies that are related to Incyte include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Immunomedics (IMMU), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Exelixis (EXEL) and Repligen (RGEN).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Medivation (MDVN), First Solar (FSLR), United Continental (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), Kite Pharma (KITE), Freeport-McMoRan (FCX) and NVIDIA (NVDA).

Incyte trades on the NASDAQ under the ticker symbol "INCY."

Incyte's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (9.48%), Bellevue Group AG (1.51%), First Trust Advisors LP (0.89%), California Public Employees Retirement System (0.71%), Bank of New York Mellon Corp (0.65%) and Two Sigma Advisers LP (0.46%). Company insiders that own Incyte stock include Barry P Flannelly, Bros Advisors Lp Baker, Dashyant Dhanak, Herve Hoppenot, Jean Jacques Bienaime, Jonathan Elliott Dickinson, Maria E Pasquale, Paul A Friedman, Paul Trower, Paula J Swain, Steven H Stein, Wendy L Dixon and Yao Wenqing.
View institutional ownership trends for Incyte.

INCY stock was sold by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Man Group plc, State of Tennessee Treasury Department, Jacobs Levy Equity Management Inc., UBS Group AG, Nuveen Asset Management LLC, Bank of Nova Scotia, and Country Trust Bank. Company insiders that have sold Incyte company stock in the last year include Barry P Flannelly, Dashyant Dhanak, Herve Hoppenot, Jonathan Elliott Dickinson, Maria E Pasquale, Paul Trower, Paula J Swain, Steven H Stein, Wendy L Dixon, and Yao Wenqing.
View insider buying and selling activity for Incyte.

INCY stock was bought by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, First Trust Advisors LP, TD Asset Management Inc., NN Investment Partners Holdings N.V., NN Investment Partners Holdings N.V., FMR LLC, Epoch Investment Partners Inc., and Vanguard Group Inc.. Company insiders that have bought Incyte stock in the last two years include Bros Advisors Lp Baker, and Jean Jacques Bienaime.
View insider buying and selling activity for Incyte.

Shares of INCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of INCY stock can currently be purchased for approximately $86.88.

Incyte has a market capitalization of $19.00 billion and generates $2.16 billion in revenue each year. The biopharmaceutical company earns $446.91 million in net income (profit) each year or $2.23 on an earnings per share basis. Incyte employs 1,456 workers across the globe.

The official website for Incyte is www.incyte.com.

Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The biopharmaceutical company can be reached via phone at 302-498-6700 or via email at [email protected]